Potential Drug Interactions in Cancer Patients Receiving Supportive Care Exclusively

Journal of Pain and Symptom Management

Volumn 35, Issue 5, 2008, Pages 535-543

  Riechelmann, Rachel P ^a   Zimmermann, Camilla ^a   Chin, Sheray N ^a   Wang, Lisa ^a   O'Carroll, Aoife ^a   Zarinehbaf, Sanaz ^a   Krzyzanowska, Monika K ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

adverse drug event; cancer; Drug interaction; drug therapy; palliative care

Indexed keywords

ACETYLSALICYLIC ACID; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIDIABETIC AGENT; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; BENZODIAZEPINE; BISPHOSPHONIC ACID DERIVATIVE; CARDIOVASCULAR AGENT; CORTICOSTEROID DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LAXATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; OPIATE; PARACETAMOL; PHENYTOIN; PROCHLORPERAZINE; RANITIDINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; WARFARIN;

ADULT; AGED; ARTICLE; BRAIN CANCER; CANCER CLASSIFICATION; CLINICAL FEATURE; COMORBIDITY; COMPUTER PROGRAM; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; DISEASE SEVERITY; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG MECHANISM; DRUG RESEARCH; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OUTPATIENT CARE; PALLIATIVE THERAPY; PATIENT CARE; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ANTICONVULSANTS; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PALLIATIVE CARE; RETROSPECTIVE STUDIES; WARFARIN;

EID: 42649093814     PISSN: 08853924     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpainsymman.2007.06.009     Document Type: Article

References (37)

1. Egger S.S., Drewe J., and Schlienger R.G. Potential drug-drug interactions in the medication of medical patients at hospital discharge. Eur J Clin Pharmacol 58 (2003) 773-778
2. Geppert U., Beindl W., Hawranek T., et al. [Drug interactions in clinical practice. A pilot project for quality assurance in prescribing]. Hautarzt 54 (2003) 53-57
3. Glintborg B., Andersen S.E., and Dalhoff K. Drug-drug interactions among recently hospitalised patients-frequent but mostly clinically insignificant. Eur J Clin Pharmacol 61 (2005) 675-681
4. Karas S. The potential for drug interactions. Ann Emerg Med 10 (1981) 627-630
5. Herr R.D., Caravati E.M., Tyler L.S., et al. Prospective evaluation of adverse drug interactions in the emergency department. Ann Emerg Med 21 (1992) 1331-1336
6. Goldberg R.M., Mabee J., Chan L., et al. Drug-drug and drug-disease interactions in the ED: analysis of a high-risk population. Am J Emerg Med 14 (1996) 447-450
7. Davidson K.W., Kahn A., and Price R.D. Reduction of adverse drug reactions by computerized drug interaction screening. J Fam Pract 25 (1987) 371-375
8. Stiztel CCR. Modern pharmacology with clinical application, Philadelphia, PA: Lippincott-Williams, 1997.
9. Haddad A., Davis M., and Lagman R. The pharmacological importance of cytochrome CYP3A4 in the palliation of symptoms: review and recommendations for avoiding adverse drug interactions. Support Care Cancer 15 (2007) 251-257
10. Buajordet I., Ebbesen J., Erikssen J., et al. Fatal adverse drug events: the paradox of drug treatment. J Intern Med 250 (2001) 327-341
11. Riechelmann R.P., Moreira F., Smaletz O., et al. Potential for drug interactions in hospitalized cancer patients. Cancer Chemother Pharmacol 56 (2005) 286-290
12. Riechelmann R.P., Tannock I.F., Wang L., et al. Potential drug interactions and duplicate prescriptions among cancer patients. J Natl Cancer Inst 99 (2007) 592-600
13. Jenkins C.A., Schulz M., Hanson J., et al. Demographic, symptom, and medication profiles of cancer patients seen by a palliative care consult team in a tertiary referral hospital. J Pain Symptom Manage 19 (2000) 174-184
14. Nauck F., Ostgathe C., Klaschik E., et al. Drugs in palliative care: results from a representative survey in Germany. Palliat Med 18 (2004) 100-107
15. Riechelmann R.P., Krzyzanowska M.K., O'Carroll A., et al. Symptom and medication profiles among cancer patients attending a palliative care clinic. Support Care Cancer 15 12 (2007) 1407-1412
16. Twycross R.G., Bergl S., John S., et al. Monitoring drug use in palliative care. Palliat Med 8 (1994) 137-143
17. Koh N.Y., and Koo W.H. Polypharmacy in palliative care: can it be reduced?. Singapore Med J 43 (2002) 279-283
18. Mercadante S., Fulfaro F., and Casuccio A. Pattern of drug use by advanced cancer patients followed at home. J Palliat Care 17 (2001) 37-40
19. Zimmermann C., Seccareccia D., Clarke A., et al. Bringing palliative care to a Canadian cancer center: the palliative care program at Princess Margaret Hospital. Support Care Cancer 14 (2006) 982-987
20. Facts and comparisons 4.0 (2006), Wolters Kluwer Health, St. Louis. http://online.factsandcomparisons.com Accessed January 23, 2007
21. Barrons R. Evaluation of personal digital assistant software for drug interactions. Am J Health Syst Pharm 61 (2004) 380-385
22. Lackner T.E. Interaction of dexamethasone with phenytoin. Pharmacotherapy 11 (1991) 344-347
23. Drummond S.H., Peterson G.M., Galloway J.G., et al. National survey of drug use in palliative care. Palliat Med 10 (1996) 119-124
24. Curtis E.B., and Walsh T.D. Prescribing practices of a palliative care service. J Pain Symptom Manage 8 (1993) 312-316
25. Williamson E.M. Interactions between herbal and conventional medicines. Expert Opin Drug Saf 4 (2005) 355-378
26. Yoon S.L., and Schaffer S.D. Herbal, prescribed, and over-the-counter drug use in older women: prevalence of drug interactions. Geriatr Nurs 27 (2006) 118-129
27. Mahe I., Bertrand N., Drouet L., et al. Paracetamol: a haemorrhagic risk factor in patients on warfarin. Br J Clin Pharmacol 59 (2005) 371-374
28. Costedoat-Chalumeau N., Amoura Z., Aymard G., et al. Potentiation of vitamin K antagonists by high-dose intravenous methylprednisolone. Ann Intern Med 132 (2000) 631-635
29. Boyer E.W., and Shannon M. The serotonin syndrome. N Engl J Med 352 (2005) 1112-1120
30. Murphy M.J., and Dominiczak M.H. Efficacy of statin therapy: possible effect of phenytoin. Postgrad Med J 75 (1999) 359-360
31. Brackett C.C., and Bloch J.D. Phenytoin as a possible cause of acetaminophen hepatotoxicity: case report and review of the literature. Pharmacotherapy 20 (2000) 229-233
32. Tenni P., Lalich D.L., and Byrne M.J. Life threatening interaction between tamoxifen and warfarin. BMJ 298 (1989) 93
33. Gerson L.B., and Triadafilopoulos G. Proton pump inhibitors and their drug interactions: an evidence-based approach. Eur J Gastroenterol Hepatol 13 (2001) 611-616
34. Edelman J., Potter J.M., and Hackett L.P. The effect of intra-articular steroids on plasma salicylate concentrations. Br J Clin Pharmacol 21 (1986) 301-307
35. White W.B. Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril. Arch Intern Med 146 (1986) 1833-1834
36. de Jong J.C., van den Berg P.B., Tobi H., et al. Combined use of SSRIs and NSAIDs increases the risk of gastrointestinal adverse effects. Br J Clin Pharmacol 55 (2003) 591-595
37. Ahmed A. Interaction between aspirin and angiotensin-converting enzyme inhibitors: should they be used together in older adults with heart failure?. J Am Geriatr Soc 50 (2002) 1293-1296